MEDTOX Scientific Increases Sales but Misses Estimates on Earnings

Seth Jayson, The Motley Fool
Updated

MEDTOX Scientific (NAS: MTOX) reported earnings on July 12. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), MEDTOX Scientific met expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share dropped.


Margins shrank across the board.

Revenue details
 MEDTOX Scientific logged revenue of $30.0 million. The two analysts polled by S&P Capital IQ expected revenue of $30.3 million on the same basis. GAAP reported sales were 7.4% higher than the prior-year quarter's $27.9 million.

anImage
anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.17. The two earnings estimates compiled by S&P Capital IQ predicted $0.21 per share. GAAP EPS of $0.14 for Q2 were 13% lower than the prior-year quarter's $0.16 per share.

anImage
anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 42.1%, 120 basis points worse than the prior-year quarter. Operating margin was 6.3%, 150 basis points worse than the prior-year quarter. Net margin was 4.1%, 90 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $30.6 million. On the bottom line, the average EPS estimate is $0.23.

Next year's average estimate for revenue is $119.3 million. The average EPS estimate is $0.78.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 154 members out of 163 rating the stock outperform, and nine members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give MEDTOX Scientific a green thumbs-up, and one give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDTOX Scientific is underperform, with an average price target of $27.00.

Over the decades, small-cap stocks, like MEDTOX Scientific have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.

The article MEDTOX Scientific Increases Sales but Misses Estimates on Earnings originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement